Document is current
Any future updates will be listed below
-
Authors
Linares, Jenniffer
Sallent-Aragay, Anna
Badia-Ramentol, Jordi
Recort-Bascuas, Alba
Méndez, Ana
Manero-Rupérez, Noemí
Re, Daniele Lo
Rivas, Elisa I.
Guiu, Marc
Zwick, Melissa
Iglesias, Mar
Martinez-Ciarpaglini, Carolina
Tarazona, Noelia
Varese, Monica
Hernando-Momblona, Xavier
Cañellas-Socias, Adrià http://orcid.org/0000-0002-8373-7803
Orrillo, Mayra
Garrido, Marta
Saoudi, Nadia
Elez, Elena http://orcid.org/0000-0002-4653-6324
Navarro, Pilar http://orcid.org/0000-0003-4314-4584
Tabernero, Josep http://orcid.org/0000-0002-2495-8139
Gomis, Roger R. http://orcid.org/0000-0001-6473-2858
Batlle, Eduard http://orcid.org/0000-0003-2422-0326
Pisonero, Jorge http://orcid.org/0000-0002-6018-4564
Cervantes, Andres http://orcid.org/0000-0003-3806-3691
Montagut, Clara
Calon, Alexandre http://orcid.org/0000-0002-3398-6131
-
Funding
Funding for this research was provided by:
Fundación Científica Asociación Española Contra el Cáncer (6884, GCAEC20030CERV)
Ministry of Economy and Competitiveness | Instituto de Salud Carlos III (PI20/00625, PI17/00211, PI20/00011, CP16/00151, CPII21/00012, MS16/00151)
Ministerio de Economía y Competitividad (PID2019-104948RB-I00)
"la Caixa" Foundation (LCF/PR/HR19/52160018)
Ministerio de Ciencia e Innovación MICINN
- License Information
-
More Information
Article History
Received: 25 January 2022
Accepted: 27 January 2023
First Online: 10 February 2023
Competing interests
: A.Ce. declares institutional research funding from Genentech, Merck Serono, Bristol Myers Squibb, Merck Sharp & Dohme, Roche, Beigene, Bayer, Servier, Lilly, Novartis, Takeda, Astellas, Takeda and Fibrogen; and advisory board or speaker fees from Amgen, Merck Serono, Roche, Bayer, Servier and Pierre Fabre in the last 5 years. J.T. reports personal financial interest in form of scientific consultancy role for Array Biopharma, AstraZeneca, Bayer, Boehringer Ingelheim, Chugai, Daiichi Sankyo, F. Hoffmann-La Roche Ltd, Genentech Inc, HalioDX SAS, Hutchison MediPharma International, Ikena Oncology, Inspirna Inc, IQVIA, Lilly, Menarini, Merck Serono, Merus, MSD, Mirati, Neophore, Novartis, Ona Therapeutics, Orion Biotechnology, Peptomyc, Pfizer, Pierre Fabre, Samsung Bioepis, Sanofi, Scandion Oncology, Scorpion Therapeutics, Seattle Genetics, Servier, Sotio Biotech, Taiho, Tessa Therapeutics and TheraMyc. Stocks: Oniria Therapeutics and also educational collaboration with Imedex/HMP, Medscape Education, MJH Life Sciences, PeerView Institute for Medical Education and Physicians Education Resource (PER). N.T. declares the following: Advisory Role: Merck Serono, Guardant Health, Speaking: Amgen, Servier, Pfizer, Merck Serono, ESMO, SEOM. C.M. reports personal financial interest in form of scientific consultancy role for Amgen, Biocartis, F. Hoffmann-La Roche Ltd, Genentech Inc, Merck Serono, Pfizer, Pierre Fabre, Sanofi, also educational collaboration with Amgen, Guardant Health, Merck Serono. The remaining authors declare no other competing interests.
